More Axil Capital's Recent News
We moved to our new office in Minato-ku, Nishi-shimbashi.
Our portfolio company, Perseus Proteomics (4882), successfully completed its IPO listing on the Tokyo Stock Exchange Mothers Board.
Our portfolio company, C4 Therapeutics (CCCC), successfully completed its IPO listing on the NASDAQ exchange.
Our portfolio company, Frequency Therapeutics (FREQ), successfully completed its IPO listing on the NASDAQ exchange.
More Portfolio Companies' Recent News
United Immunity completed Series B round.
United Immunity has entered into a joint research agreement with Xyphos/Astellas on cancer immunotherapy program.
United Immunity completed Series A2 round.
AIBIOS is working on three active programs to resolve unmet medical needs.
© Axil Capital All Rights Reserved
